Zhuo-Xun Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10717487/publications.pdf

Version: 2024-02-01

759233 713466 28 507 12 21 citations h-index g-index papers 28 28 28 288 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	ATPâ€binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine, 2021, 14, 232-256.	1.8	57
2	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology, 2019, 166, 120-127.	4.4	52
3	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers, 2020, 12, 186.	3.7	33
4	Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. Frontiers in Oncology, 2020, 10, 955.	2.8	31
5	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. Frontiers in Oncology, 2019, 9, 514.	2.8	29
6	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. Frontiers in Oncology, 2020, 10, 700.	2.8	25
7	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1387.	4.1	25
8	Modulating the function of ABCB1: <i>in vitro</i> and <i>in vivo</i> characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications, 2020, 40, 285-300.	9.2	24
9	Dual TTK/CLK2 inhibitor, CCâ€671, selectively antagonizes ABCG2â€mediated multidrug resistance in lung cancer cells. Cancer Science, 2020, 111, 2872-2882.	3.9	24
10	Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. Cancers, 2020, 12, 3249.	3.7	19
11	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. Frontiers in Oncology, 2020, 10, 674.	2.8	18
12	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Frontiers in Oncology, 2020, 10, 574861.	2.8	16
13	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. Frontiers in Oncology, 2020, 10, 228.	2.8	15
14	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. MedComm, 2021, 2, 765-777.	7.2	15
15	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. Experimental Cell Research, 2020, 388, 111858.	2.6	14
16	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. Frontiers in Pharmacology, 2020, 11, 615824.	3.5	14
17	Drug resistance: from bacteria to cancer. Molecular Biomedicine, 2021, 2, 27.	4.4	14
18	Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. Frontiers in Oncology, 2020, 10, 624954.	2.8	13

#	Article	IF	CITATIONS
19	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine and Pharmacotherapy, 2021, 136, 111223.	5.6	12
20	Overexpression of ABCC1 Confers Drug Resistance to Betulin. Frontiers in Oncology, 2021, 11, 640656.	2.8	11
21	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology, 2021, 12, 620874.	3.5	8
22	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Frontiers in Cell and Developmental Biology, 2021, 9, 697927.	3.7	8
23	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Frontiers in Pharmacology, 2022, 13, 861642.	3.5	7
24	MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: InÂvitro and inÂvivo study. Acta Pharmaceutica Sinica B, 2022, 12, 2609-2618.	12.0	7
25	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. Frontiers in Oncology, 2021, 11, 731260.	2.8	6
26	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular Cancer, 2022, 21, 40.	19.2	5
27	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. International Journal of Biological Sciences, 2021, 17, 2652-2665.	6.4	4
28	Paclitaxel and chemoresistance. , 2022, , 251-267.		1